New engineered T cell tool helps fight solid tumors
A new T cell-agonist chimera (SNTC) activates STING to improve cancer immunotherapy.
Researchers developed an engineered T cell-agonist chimera (SNTC). This tool aims to improve adoptive T cell therapy against solid tumors.
The SNTC uses a TAM-targeted nanoagonist. This nanoagonist is attached to the T cell surface via covalent surface anchoring. It is released in tumor tissue due to elevated reduction potential on the T cell surface.
STING stands for stimulator of interferon genes. TAM stands for tumor-associated macrophages. These macrophages are part of the tumor microenvironment.
The nanoagonist is restored inside TAM by intracellular glutathione-mediated restoration. This allows for AND logic-gated STING activation. This process enhances the antigen presentation ability of TAM to activate endogenous T cells.
In mice with melanoma, SNTC resulted in over survival beyond 60 d. Combining tumor-infiltrating T lymphocyte (TIL)-based SNTC with immune checkpoint blockade therapy led to sustained tumor regression in a mouse model of orthotopic pancreatic tumor.
Key facts
- SNTC achieves synchronized biodistribution of STING agonist with adoptive T cells.
- The tool reshapes tumor stroma and the immunosuppressive tumor microenvironment.
- SNTC showed over survival beyond 60 d in melanoma tumor-bearing mice.